novocure(NVCR) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Novocure Reports First Quarter 2024 Financial Results Quarterly net revenues of $139 million, up 13% year-over-year, with 3,845 active patients on therapy as of March 31, 2024 Phase 3 METIS trial in brain metastases from non-small cell lung cancer met primary endpoint and will be presented as late-breaking abstract at ASCO 2024 LUNAR PMA application for TTFields in NSCLC Day 100 FDA meeting complete Root, Switzerland – Novocure (NASDAQ: NVCR) today reported financial results for the quarter end ...